Canaccord lowered the firm’s price target on Kenvue to $27 from $28 and keeps a Buy rating on the shares. The firm said they reported mixed Q3 results and they narrowed its annual guidance due to challenges in China, FX, and what we believe is weakness in the Neutrogena brand that will take time to recover as innovation is rolled out.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KVUE: